Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations

Alberto Papi, Stefano Petruzzelli, Stefano Vezzoli, George Georges, Leonardo M. Fabbri

Source: Eur Respir J, 53 (4) 1900147; 10.1183/13993003.00147-2019
Journal Issue: April
Disease area: Airway diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Alberto Papi, Stefano Petruzzelli, Stefano Vezzoli, George Georges, Leonardo M. Fabbri. Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations. Eur Respir J, 53 (4) 1900147; 10.1183/13993003.00147-2019

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation
Source: Eur Respir J, 53 (5) 1900235; 10.1183/13993003.00235-2019
Year: 2019



β-blockers and risk of COPD exacerbation requiring hospitalisation in patients with COPD
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011

Impact of moderate and severe exacerbations in severe COPD patients
Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD?
Year: 2018




Predictors of severe exacerbations in patients with moderate and severe asthma
Source: International Congress 2018 – Determinants and monitoring of asthma control
Year: 2018



Severe outcomes of COVID-19 among patients with COPD and asthma
Source: ERJ Open Res, 7 (1) 00594-2020; 10.1183/23120541.00594-2020
Year: 2021



Use of adjunct cardiovascular therapy in patients hospitalised for acute exacerbations of COPD
Source: ERJ Open Res, 4 (3) 00087-2018; 10.1183/23120541.00087-2018
Year: 2018



Long-term effect of roflumilast on exacerbations in patients with severe to very severe COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 526s
Year: 2006

Markers of T2-inflammation in patients with severe asthma and concomitant COPD
Source: Virtual Congress 2020 – News on clinical evaluation of bronchiectasis, cough and inflammatory disease
Year: 2020


Predictors of exacerbations requiring hospitalisation in patients with stable COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 177s
Year: 2006

The 1-year cost-effectiveness of roflumilast for the treatment of severe to very severe COPD patients
Source: Eur Respir J 2007; 30: Suppl. 51, 194s
Year: 2007

COPD on anti-GERD therapy remains at higher risk for severe exacerbation
Source: International Congress 2014 – COPD exacerbations
Year: 2014

Six months azithromycin treatment in COPD patients with high risk of further exacerbations
Source: International Congress 2017 – Management of COPD
Year: 2017


Cost analysis for inpatient therapy in elderly patients with acute exacerbations of chronic obstructive pulmonary disease
Source: Eur Respir J 2004; 24: Suppl. 48, 661s
Year: 2004

Statins and outcome of COPD patients after hospitalization for COPD exacerbations
Source: Annual Congress 2010 - New treatments for asthma and COPD
Year: 2010


Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy
Source: International Congress 2015 – Advances in the future treatment of COPD
Year: 2015

Osteoporosis risk associated with chronic corticoid inhalation therapy in patients with COPD
Source: Annual Congress 2009 - Prognosis and comorbidities in COPD
Year: 2009


Two-year safety of targeted lung denervation in patients with moderate to severe COPD
Source: International Congress 2015 – Bronchoscopic treatment of COPD and asthma: valves, coils, thermoplastics and something more
Year: 2015

Combined therapy of severe osteoporosis for patients with bronchial asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 47s
Year: 2001

Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD
Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management
Year: 2013